Last quarter (Q ), CTT Pharmaceutical Holdings's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, CTT Pharmaceutical Holdings's net income was $-1.09M. See CTT Pharmaceutical Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 15	Dec 14	Dec 13	Dec 12	Dec 11
Total Revenue	$ 40.00K	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	-	$ 0.00	$ 0.00	$ 0.00
Operating Expense	$ 1.39M	$ 1.45M	$ 672.16K	$ 18.91K	$ 1.09M	$ 757.93K
Operating Income	$ -1.35M	$ -1.45M	$ -672.16K	$ -18.91K	$ -1.09M	$ -757.93K
Net Non Operating Interest Income Expense	-	-	-	$ 1.65K	$ 53.00	$ 6.67K
Other Income Expense	$ -1.01K	-	$ 900.00K	$ 16.62K	$ 91.67K	$ 4.49M
Pretax Income	$ -1.35M	$ -1.45M	$ 227.84K	$ -18.91K	$ -1.00M	$ 3.74M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -1.35M	$ -1.45M	$ 227.84K	$ -18.91K	$ -1.00M	$ 3.74M
Basic EPS	$ -0.01	$ -0.07	$ 0.01	$ 0.10	$ -1.10	$ 4.20
Diluted EPS	$ -0.01	$ -0.07	$ 0.01	$ 0.10	$ -1.10	$ 4.00
Basic Average Shares	-	$ 20.87M	$ 16.34M	$ 941.36K	$ 941.26K	$ 892.06K
Diluted Average Shares	-	$ 20.87M	$ 16.34M	$ 941.36K	$ 941.26K	$ 949.25K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 1.39M	$ 1.45M	$ 672.16K	$ 18.91K	$ 1.09M	$ 757.93K
Interest Expense	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	$ -1.35M	$ -1.45M	$ 227.84K	$ -18.91K	$ -1.00M	$ 3.74M
Normalized Income	$ -1.35M	$ -1.45M	$ -447.16K	$ -18.91K	$ -1.09M	$ -737.87K
EBIT	$ -1.35M	$ -1.45M	$ -672.16K	$ -18.91K	$ -1.09M	$ -757.93K
EBITDA	$ -1.35M	$ -1.45M	$ -672.16K	$ -18.91K	$ -1.09M	$ -757.93K

Currency in USD

CTT Pharmaceutical Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing